ID   PTPS_HUMAN              Reviewed;         145 AA.
AC   Q03393; B0YJ87; Q8WVG8;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   04-FEB-2015, entry version 156.
DE   RecName: Full=6-pyruvoyl tetrahydrobiopterin synthase;
DE            Short=PTP synthase;
DE            Short=PTPS;
DE            EC=4.2.3.12;
GN   Name=PTS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND CATALYTIC ACTIVITY.
RC   TISSUE=Liver;
RX   PubMed=1282802; DOI=10.1016/0006-291X(92)90235-D;
RA   Thoeny B., Leimbacher W., Buergisser D., Heizmann C.W.;
RT   "Human 6-pyruvoyltetrahydropterin synthase: cDNA cloning and
RT   heterologous expression of the recombinant enzyme.";
RL   Biochem. Biophys. Res. Commun. 189:1437-1443(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8216273; DOI=10.1006/bbrc.1993.2197;
RA   Ashida A., Hatakeyama K., Kagamiyama H.;
RT   "cDNA cloning, expression in Escherichia coli and purification of
RT   human 6-pyruvoyl-tetrahydropterin synthase.";
RL   Biochem. Biophys. Res. Commun. 195:1386-1393(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT HPABH4A VAL-114.
RX   PubMed=7698774; DOI=10.1006/geno.1994.1642;
RA   Ashida A., Owada M., Hatakeyama K.;
RT   "A missense mutation (A to G) of 6-pyruvoyltetrahydropterin synthase
RT   in tetrahydrobiopterin-deficient form of hyperphenylalaninemia.";
RL   Genomics 24:408-410(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8841415; DOI=10.1111/j.1432-1033.1996.0477h.x;
RA   Kluge C., Brecevic L., Heizmann C.W., Blau N., Thoeny B.;
RT   "Chromosomal localization, genomic structure and characterization of
RT   the human gene and a retropseudogene for 6-pyruvoyltetrahydropterin
RT   synthase.";
RL   Eur. J. Biochem. 240:477-484(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Liu T.T., Lu S.F., Hsiao K.J.;
RT   "Genomic structure of 6-pyruvoyl-tetrahydropterin synthase gene and a
RT   T/C polymorphism detected in Chinese.";
RL   J. Biomed. Lab. Sci. 10:39-47(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Hsiao K.-J., Liu T.-T., Chang Y.-H., Chiu Y.-H., Chiang S.-H.,
RA   Chang H.-M., Chen C.-Y., Tsai S.-F.;
RT   "Isolation and sequencing of human 6-pyruvoyl-tetrahydropterin
RT   synthase gene containing BAC clone 321H15.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   CHARACTERIZATION OF VARIANTS HPABH4A CYS-16 AND GLN-25, KINETIC
RP   PARAMETERS, PHOSPHORYLATION AT SER-19, AND MUTAGENESIS OF SER-19.
RX   PubMed=10531334; DOI=10.1074/jbc.274.44.31341;
RA   Scherer-Oppliger T., Leimbacher W., Blau N., Thoeny B.;
RT   "Serine 19 of human 6-pyruvoyltetrahydropterin synthase is
RT   phosphorylated by cGMP protein kinase II.";
RL   J. Biol. Chem. 274:31341-31348(1999).
RN   [13]
RP   REVIEW ON VARIANTS.
RX   PubMed=9222755;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:1<11::AID-HUMU2>3.0.CO;2-P;
RA   Thoeny B., Blau N.;
RT   "Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin
RT   synthase genes.";
RL   Hum. Mutat. 10:11-20(1997).
RN   [14]
RP   VARIANTS HPABH4A CYS-16 AND GLN-25.
RX   PubMed=8178819;
RA   Thoeny B., Leimbacher W., Blau N., Harvie A., Heizmann C.W.;
RT   "Hyperphenylalaninemia due to defects in tetrahydrobiopterin
RT   metabolism: molecular characterization of mutations in 6-pyruvoyl-
RT   tetrahydropterin synthase.";
RL   Am. J. Hum. Genet. 54:782-792(1994).
RN   [15]
RP   CHARACTERIZATION OF VARIANTS HPABH4A CYS-16; GLN-25; VAL-57 DEL AND
RP   LEU-87.
RX   PubMed=7493990; DOI=10.1074/jbc.270.49.29498;
RA   Oppliger T., Thoeny B., Nar H., Buergisser D., Huber R.,
RA   Heizmann C.W., Blau N.;
RT   "Structural and functional consequences of mutations in 6-
RT   pyruvoyltetrahydropterin synthase causing hyperphenylalaninemia in
RT   humans. Phosphorylation is a requirement for in vivo activity.";
RL   J. Biol. Chem. 270:29498-29506(1995).
RN   [16]
RP   VARIANTS HPABH4A SER-52 AND SER-87.
RX   PubMed=8707300; DOI=10.1007/s004390050213;
RA   Liu T.T., Hsiao K.J.;
RT   "Identification of a common 6-pyruvoyl-tetrahydropterin synthase
RT   mutation at codon 87 in Chinese phenylketonuria caused by
RT   tetrahydrobiopterin synthesis deficiency.";
RL   Hum. Genet. 98:313-316(1996).
RN   [17]
RP   VARIANTS HPABH4A VAL-57 DEL; MET-67; GLU-129 AND VAL-136.
RX   PubMed=9222757;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:1<25::AID-HUMU4>3.0.CO;2-L;
RA   Oppliger T., Thoeny B., Kluge C., Matasovic A., Heizmann C.W.,
RA   Ponzone A., Spada M., Blau N.;
RT   "Identification of mutations causing 6-pyruvoyl-tetrahydropterin
RT   synthase deficiency in four Italian families.";
RL   Hum. Mutat. 10:25-35(1997).
RN   [18]
RP   VARIANT HPABH4A VAL-114.
RX   PubMed=9159737; DOI=10.1002/mds.870120321;
RA   Hanihara T., Inoue K., Kawanishi C., Sugiyama N., Miyakawa T.,
RA   Onishi H., Yamada Y., Osaka H., Kosaka K., Iwabuchi K., Owada M.;
RT   "6-pyruvoyl-tetrahydropterin synthase deficiency with generalized
RT   dystonia and diurnal fluctuation of symptoms: a clinical and molecular
RT   study.";
RL   Mov. Disord. 12:408-411(1997).
RN   [19]
RP   VARIANTS HPABH4A GLY-25; SER-52; MET-56; ASP-70; SER-87; ASN-96 AND
RP   MET-106.
RX   PubMed=9450907;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:1<76::AID-HUMU12>3.0.CO;2-W;
RA   Liu T.-T., Hsiao K.-J., Lu S.-F., Wu S.-J., Wu K.-F., Chiang S.-H.,
RA   Liu X.-Q., Chen R.-G., Yu W.-M.;
RT   "Mutation analysis of the 6-pyruvoyl-tetrahydropterin synthase gene in
RT   Chinese hyperphenylalaninemia caused by tetrahydrobiopterin synthesis
RT   deficiency.";
RL   Hum. Mutat. 11:76-83(1998).
RN   [20]
RP   VARIANTS HPABH4A VAL-57 DEL AND MET-97.
RX   PubMed=10585341;
RA   Romstad A., Guldberg P., Blau N., Guettler F.;
RT   "Single-step mutation scanning of the 6-pyruvoyltetrahydropterin
RT   synthase gene in patients with hyperphenylalaninemia.";
RL   Clin. Chem. 45:2102-2108(1999).
RN   [21]
RP   VARIANTS HPABH4A ASP-47 AND GLY-116.
RX   PubMed=10220141;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:4<286::AID-HUMU4>3.0.CO;2-C;
RA   Scherer-Oppliger T., Matasovic A., Laufs S., Levy H.L.,
RA   Quackenbush E.J., Blau N., Thoeny B.;
RT   "Dominant negative allele (N47D) in a compound heterozygote for a
RT   variant of 6-pyruvoyltetrahydropterin synthase deficiency causing
RT   transient hyperphenylalaninemia.";
RL   Hum. Mutat. 13:286-289(1999).
RN   [22]
RP   VARIANT HPABH4A CYS-99.
RX   PubMed=10874306;
RX   DOI=10.1002/1098-1004(200007)16:1<54::AID-HUMU10>3.0.CO;2-C;
RA   Blau N., Scherer-Oppliger T., Baumer A., Riegel M., Matasovic A.,
RA   Schinzel A., Jaeken J., Thoeny B.;
RT   "Isolated central form of tetrahydrobiopterin deficiency associated
RT   with hemizygosity on chromosome 11q and a mutant allele of PTPS.";
RL   Hum. Mutat. 16:54-60(2000).
RN   [23]
RP   VARIANTS HPABH4A PHE-26; MET-67; LEU-87; LEU-124; GLY-136 AND VAL-136.
RX   PubMed=11388593; DOI=10.1007/s004310000722;
RA   Dudesek A., Roeschinger W., Muntau A.C., Seidel J., Leupold D.,
RA   Thoeny B., Blau N.;
RT   "Molecular analysis and long-term follow-up of patients with different
RT   forms of 6-pyruvoyl-tetrahydropterin synthase deficiency.";
RL   Eur. J. Pediatr. 160:267-276(2001).
CC   -!- FUNCTION: Involved in the biosynthesis of tetrahydrobiopterin, an
CC       essential cofactor of aromatic amino acid hydroxylases. Catalyzes
CC       the transformation of 7,8-dihydroneopterin triphosphate into 6-
CC       pyruvoyl tetrahydropterin. {ECO:0000269|PubMed:1282802}.
CC   -!- CATALYTIC ACTIVITY: 7,8-dihydroneopterin 3'-triphosphate = 6-
CC       pyruvoyl-5,6,7,8-tetrahydropterin + triphosphate.
CC       {ECO:0000269|PubMed:1282802}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=8.1 uM for 7,8-dihydroneopterin triphosphate
CC         {ECO:0000269|PubMed:10531334};
CC         Vmax=120 nmol/min/mg enzyme {ECO:0000269|PubMed:10531334};
CC   -!- PATHWAY: Cofactor biosynthesis; tetrahydrobiopterin biosynthesis;
CC       tetrahydrobiopterin from 7,8-dihydroneopterin triphosphate: step
CC       1/3.
CC   -!- SUBUNIT: Homohexamer formed of two homotrimers in a head to head
CC       fashion.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-712344, EBI-712344;
CC   -!- PTM: Phosphorylation of Ser-19 is required for maximal enzyme
CC       activity. {ECO:0000269|PubMed:10531334,
CC       ECO:0000269|PubMed:18669648, ECO:0000269|PubMed:20068231}.
CC   -!- DISEASE: Hyperphenylalaninemia, BH4-deficient, A (HPABH4A)
CC       [MIM:261640]: An autosomal recessive disorder characterized by
CC       hyperphenylalaninemia, depletion of the neurotransmitters dopamine
CC       and serotonin, and progressive cognitive and motor deficits.
CC       Neurological symptoms are unresponsive to the classic
CC       phenylalanine-low diet. {ECO:0000269|PubMed:10220141,
CC       ECO:0000269|PubMed:10585341, ECO:0000269|PubMed:10874306,
CC       ECO:0000269|PubMed:11388593, ECO:0000269|PubMed:7698774,
CC       ECO:0000269|PubMed:8178819, ECO:0000269|PubMed:8707300,
CC       ECO:0000269|PubMed:9159737, ECO:0000269|PubMed:9222757,
CC       ECO:0000269|PubMed:9450907}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The active site is at the interface between 2
CC       subunits. The proton acceptor Cys is on one subunit, and the
CC       charge relay system is on the other subunit.
CC   -!- SIMILARITY: Belongs to the PTPS family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M97655; AAA51541.1; -; mRNA.
DR   EMBL; D17400; BAA04224.1; -; mRNA.
DR   EMBL; D25234; BAA04959.1; -; Genomic_DNA.
DR   EMBL; L76259; AAB64229.1; -; Genomic_DNA.
DR   EMBL; U63383; AAC16970.1; -; Genomic_DNA.
DR   EMBL; U63380; AAC16970.1; JOINED; Genomic_DNA.
DR   EMBL; U63381; AAC16970.1; JOINED; Genomic_DNA.
DR   EMBL; U63382; AAC16970.1; JOINED; Genomic_DNA.
DR   EMBL; AB042297; BAA95486.1; -; Genomic_DNA.
DR   EMBL; EF445018; ACA06065.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67195.1; -; Genomic_DNA.
DR   EMBL; BC009686; AAH09686.1; -; mRNA.
DR   EMBL; BC018029; AAH18029.1; -; mRNA.
DR   CCDS; CCDS8359.1; -.
DR   PIR; JC1405; JC1405.
DR   RefSeq; NP_000308.1; NM_000317.2.
DR   UniGene; Hs.503860; -.
DR   PDB; 3I2B; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J/K/L=7-145.
DR   PDBsum; 3I2B; -.
DR   ProteinModelPortal; Q03393; -.
DR   SMR; Q03393; 8-145.
DR   BioGrid; 111769; 17.
DR   IntAct; Q03393; 3.
DR   MINT; MINT-1419639; -.
DR   STRING; 9606.ENSP00000280362; -.
DR   PhosphoSite; Q03393; -.
DR   MaxQB; Q03393; -.
DR   PaxDb; Q03393; -.
DR   PRIDE; Q03393; -.
DR   DNASU; 5805; -.
DR   Ensembl; ENST00000280362; ENSP00000280362; ENSG00000150787.
DR   GeneID; 5805; -.
DR   KEGG; hsa:5805; -.
DR   UCSC; uc001pnj.4; human.
DR   CTD; 5805; -.
DR   GeneCards; GC11P112097; -.
DR   HGNC; HGNC:9689; PTS.
DR   HPA; HPA001481; -.
DR   MIM; 261640; phenotype.
DR   MIM; 612719; gene.
DR   neXtProt; NX_Q03393; -.
DR   Orphanet; 13; 6-pyruvoyl-tetrahydropterin synthase deficiency.
DR   PharmGKB; PA34032; -.
DR   eggNOG; COG0720; -.
DR   GeneTree; ENSGT00390000002752; -.
DR   HOGENOM; HOG000225069; -.
DR   HOVERGEN; HBG004358; -.
DR   InParanoid; Q03393; -.
DR   KO; K01737; -.
DR   OMA; CHRLHSK; -.
DR   OrthoDB; EOG7NSB3V; -.
DR   PhylomeDB; Q03393; -.
DR   TreeFam; TF105796; -.
DR   BioCyc; MetaCyc:HS07692-MONOMER; -.
DR   BRENDA; 4.2.3.12; 2681.
DR   Reactome; REACT_111176; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation.
DR   SABIO-RK; Q03393; -.
DR   UniPathway; UPA00849; UER00819.
DR   EvolutionaryTrace; Q03393; -.
DR   GeneWiki; PTS_(gene); -.
DR   GenomeRNAi; 5805; -.
DR   NextBio; 22628; -.
DR   PRO; PR:Q03393; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; Q03393; -.
DR   CleanEx; HS_PTS; -.
DR   ExpressionAtlas; Q03393; baseline and differential.
DR   Genevestigator; Q03393; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:LIFEdb.
DR   GO; GO:0003874; F:6-pyruvoyltetrahydropterin synthase activity; TAS:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006520; P:cellular amino acid metabolic process; TAS:ProtInc.
DR   GO; GO:0007417; P:central nervous system development; TAS:ProtInc.
DR   GO; GO:0046209; P:nitric oxide metabolic process; TAS:Reactome.
DR   GO; GO:0050999; P:regulation of nitric-oxide synthase activity; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006729; P:tetrahydrobiopterin biosynthetic process; TAS:ProtInc.
DR   InterPro; IPR007115; 6-PTP_synth/QueD.
DR   InterPro; IPR022470; PTPS_Cys_AS.
DR   InterPro; IPR022469; PTPS_His_AS.
DR   PANTHER; PTHR12589; PTHR12589; 1.
DR   Pfam; PF01242; PTPS; 1.
DR   PIRSF; PIRSF006113; PTP_synth; 1.
DR   TIGRFAMs; TIGR00039; 6PTHBS; 1.
DR   PROSITE; PS00987; PTPS_1; 1.
DR   PROSITE; PS00988; PTPS_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disease mutation; Lyase;
KW   Metal-binding; Phenylketonuria; Phosphoprotein; Reference proteome;
KW   Tetrahydrobiopterin biosynthesis; Zinc.
FT   CHAIN         1    145       6-pyruvoyl tetrahydrobiopterin synthase.
FT                                /FTId=PRO_0000057914.
FT   ACT_SITE     43     43       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10123}.
FT   ACT_SITE     90     90       Charge relay system.
FT                                {ECO:0000255|PROSITE-ProRule:PRU10124}.
FT   ACT_SITE    134    134       Charge relay system.
FT                                {ECO:0000255|PROSITE-ProRule:PRU10124}.
FT   METAL        24     24       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10123}.
FT   METAL        49     49       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10123}.
FT   METAL        51     51       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10123}.
FT   MOD_RES      19     19       Phosphoserine; by PKG.
FT                                {ECO:0000269|PubMed:10531334,
FT                                ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   VARIANT      16     16       R -> C (in HPABH4A; severe decrease in
FT                                activity; diminishes phosphorylation by
FT                                PKG). {ECO:0000269|PubMed:10531334,
FT                                ECO:0000269|PubMed:7493990,
FT                                ECO:0000269|PubMed:8178819}.
FT                                /FTId=VAR_006816.
FT   VARIANT      25     25       R -> G (in HPABH4A; severe form).
FT                                {ECO:0000269|PubMed:9450907}.
FT                                /FTId=VAR_006817.
FT   VARIANT      25     25       R -> Q (in HPABH4A; abolishes activity;
FT                                no effect on phosphorylation by PKG).
FT                                {ECO:0000269|PubMed:10531334,
FT                                ECO:0000269|PubMed:7493990,
FT                                ECO:0000269|PubMed:8178819}.
FT                                /FTId=VAR_006818.
FT   VARIANT      26     26       L -> F (in HPABH4A).
FT                                {ECO:0000269|PubMed:11388593}.
FT                                /FTId=VAR_058265.
FT   VARIANT      35     35       E -> G (in HPABH4A).
FT                                /FTId=VAR_006819.
FT   VARIANT      36     36       N -> K (in HPABH4A).
FT                                /FTId=VAR_006820.
FT   VARIANT      47     47       N -> D (in HPABH4A; transient phenotype;
FT                                due to partial PTS deficiency; total loss
FT                                of activity).
FT                                {ECO:0000269|PubMed:10220141}.
FT                                /FTId=VAR_008040.
FT   VARIANT      52     52       N -> S (in HPABH4A; severe form; common
FT                                in Chinese population).
FT                                {ECO:0000269|PubMed:8707300,
FT                                ECO:0000269|PubMed:9450907}.
FT                                /FTId=VAR_006821.
FT   VARIANT      56     56       V -> M (in HPABH4A; mild form).
FT                                {ECO:0000269|PubMed:9450907}.
FT                                /FTId=VAR_006822.
FT   VARIANT      57     57       Missing (in HPABH4A).
FT                                {ECO:0000269|PubMed:10585341,
FT                                ECO:0000269|PubMed:7493990,
FT                                ECO:0000269|PubMed:9222757}.
FT                                /FTId=VAR_006823.
FT   VARIANT      67     67       T -> M (in HPABH4A).
FT                                {ECO:0000269|PubMed:11388593,
FT                                ECO:0000269|PubMed:9222757}.
FT                                /FTId=VAR_006824.
FT   VARIANT      70     70       V -> D (in HPABH4A).
FT                                {ECO:0000269|PubMed:9450907}.
FT                                /FTId=VAR_006825.
FT   VARIANT      87     87       P -> L (in HPABH4A).
FT                                {ECO:0000269|PubMed:11388593,
FT                                ECO:0000269|PubMed:7493990}.
FT                                /FTId=VAR_006826.
FT   VARIANT      87     87       P -> S (in HPABH4A; severe form; common
FT                                in Chinese population;
FT                                dbSNP:rs104894276).
FT                                {ECO:0000269|PubMed:8707300,
FT                                ECO:0000269|PubMed:9450907}.
FT                                /FTId=VAR_006827.
FT   VARIANT      96     96       D -> N (in HPABH4A; severe form;
FT                                dbSNP:rs104894280).
FT                                {ECO:0000269|PubMed:9450907}.
FT                                /FTId=VAR_006828.
FT   VARIANT      97     97       V -> M (in HPABH4A).
FT                                {ECO:0000269|PubMed:10585341}.
FT                                /FTId=VAR_058266.
FT   VARIANT      99     99       Y -> C (in HPABH4A).
FT                                {ECO:0000269|PubMed:10874306}.
FT                                /FTId=VAR_058267.
FT   VARIANT     100    100       F -> V (in HPABH4A).
FT                                /FTId=VAR_006829.
FT   VARIANT     106    106       T -> M (in HPABH4A).
FT                                {ECO:0000269|PubMed:9450907}.
FT                                /FTId=VAR_006830.
FT   VARIANT     114    114       I -> V (in HPABH4A).
FT                                {ECO:0000269|PubMed:7698774,
FT                                ECO:0000269|PubMed:9159737}.
FT                                /FTId=VAR_006831.
FT   VARIANT     116    116       D -> G (in HPABH4A; due to partial PTS
FT                                deficiency; mild form).
FT                                {ECO:0000269|PubMed:10220141}.
FT                                /FTId=VAR_008041.
FT   VARIANT     124    124       V -> L (in HPABH4A).
FT                                {ECO:0000269|PubMed:11388593}.
FT                                /FTId=VAR_058268.
FT   VARIANT     129    129       K -> E (in HPABH4A).
FT                                {ECO:0000269|PubMed:9222757}.
FT                                /FTId=VAR_006832.
FT   VARIANT     136    136       D -> G (in HPABH4A).
FT                                {ECO:0000269|PubMed:11388593}.
FT                                /FTId=VAR_058269.
FT   VARIANT     136    136       D -> V (in HPABH4A).
FT                                {ECO:0000269|PubMed:11388593,
FT                                ECO:0000269|PubMed:9222757}.
FT                                /FTId=VAR_006833.
FT   MUTAGEN      19     19       S->A: Decrease in activity; abolishes
FT                                phosphorylation by PKG.
FT                                {ECO:0000269|PubMed:10531334}.
FT   CONFLICT    114    114       I -> M (in Ref. 9; AAH18029).
FT                                {ECO:0000305}.
FT   STRAND       11     24       {ECO:0000244|PDB:3I2B}.
FT   STRAND       29     31       {ECO:0000244|PDB:3I2B}.
FT   HELIX        33     40       {ECO:0000244|PDB:3I2B}.
FT   HELIX        41     44       {ECO:0000244|PDB:3I2B}.
FT   STRAND       49     62       {ECO:0000244|PDB:3I2B}.
FT   TURN         65     67       {ECO:0000244|PDB:3I2B}.
FT   HELIX        73     83       {ECO:0000244|PDB:3I2B}.
FT   HELIX        85     88       {ECO:0000244|PDB:3I2B}.
FT   HELIX        93     96       {ECO:0000244|PDB:3I2B}.
FT   HELIX        98    101       {ECO:0000244|PDB:3I2B}.
FT   HELIX       107    119       {ECO:0000244|PDB:3I2B}.
FT   STRAND      127    135       {ECO:0000244|PDB:3I2B}.
FT   STRAND      138    142       {ECO:0000244|PDB:3I2B}.
SQ   SEQUENCE   145 AA;  16386 MW;  A1CD0DC2F83187E0 CRC64;
     MSTEGGGRRC QAQVSRRISF SASHRLYSKF LSDEENLKLF GKCNNPNGHG HNYKVVVTVH
     GEIDPATGMV MNLADLKKYM EEAIMQPLDH KNLDMDVPYF ADVVSTTENV AVYIWDNLQK
     VLPVGVLYKV KVYETDNNIV VYKGE
//
